New hope for kids with resistant cancers: experimental drug CUDC-907 tested
NCT ID NCT02909777
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This early-stage trial tested a new drug called CUDC-907 in 26 children and young adults (ages 1-21) whose solid tumors, brain tumors, or lymphoma had stopped responding to standard treatments. The main goal was to find the safest dose and identify side effects. Researchers also looked at how long the drug kept the cancer from growing and how the body processed it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Texas Children's, Baylor College of Medicine
Houston, Texas, 77030, United States
-
University of California, San Francisco, Benioff Children's Hospital
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.